Lipvas F 10mg/160mg Tablet is a combination lipid-lowering agent containing Atorvastatin 10mg and Fenofibrate 160mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Atorvastatin, a selective HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Fenofibrate, a fibric acid derivative, primarily decreases triglyceride levels and increases HDL-C by activating peroxisome proliferator-activated receptor alpha (PPARα), enhancing lipolysis and elimination of triglyceride-rich particles. The combined formulation targets multiple lipid abnormalities, offering comprehensive control of cholesterol and triglyceride levels in patients inadequately managed by monotherapy. Lipvas F is particularly beneficial in patients with mixed dyslipidemia, including those with elevated LDL-C and hypertriglyceridemia, reducing cardiovascular risk. The medication should be administered orally once daily, preferably with food to enhance absorption. Caution is advised in patients with hepatic or renal impairment, and periodic monitoring of liver function tests, renal parameters, and muscle enzymes is recommended to detect potential adverse effects such as hepatotoxicity or myopathy. Lipvas F should be used as part of a comprehensive treatment plan including diet, exercise, and lifestyle modification.